These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 16476828)
1. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Szarfman A; Doraiswamy PM; Tonning JM; Levine JG Arch Neurol; 2006 Feb; 63(2):299-300; author reply 300. PubMed ID: 16476828 [No Abstract] [Full Text] [Related]
2. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine]. Montastruc JL; Schmitt L; Bagheri H Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874 [TBL] [Abstract][Full Text] [Related]
3. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
5. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Voon V; Hassan K; Zurowski M; Duff-Canning S; de Souza M; Fox S; Lang AE; Miyasaki J Neurology; 2006 Jun; 66(11):1750-2. PubMed ID: 16769956 [TBL] [Abstract][Full Text] [Related]
8. Gambling and Parkinson disease. Lu C; Bharmal A; Suchowersky O Arch Neurol; 2006 Feb; 63(2):298. PubMed ID: 16476827 [No Abstract] [Full Text] [Related]
9. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Toth C; Breithaupt K; Ge S; Duan Y; Terris JM; Thiessen A; Wiebe S; Zochodne DW; Suchowersky O Ann Neurol; 2010 Jul; 68(1):28-36. PubMed ID: 20582991 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease--where do we go from here? Suchowersky O Nat Clin Pract Neurol; 2006 Sep; 2(9):461. PubMed ID: 16932605 [No Abstract] [Full Text] [Related]
11. Pathological gambling caused by drugs used to treat Parkinson disease. Dodd ML; Klos KJ; Bower JH; Geda YE; Josephs KA; Ahlskog JE Arch Neurol; 2005 Sep; 62(9):1377-81. PubMed ID: 16009751 [TBL] [Abstract][Full Text] [Related]
12. Adverse reactions to levodopa: drug toxicity or progression of disease? Agid Y; Chase T; Marsden D Lancet; 1998 Mar; 351(9106):851-2. PubMed ID: 9525359 [No Abstract] [Full Text] [Related]
14. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease]. Klivényi P; Vécsei L Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097 [TBL] [Abstract][Full Text] [Related]
15. Levodopa therapeutics for Parkinson's disease: new developments. LeWitt PA Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040 [TBL] [Abstract][Full Text] [Related]
16. Levodopa elevates homocysteine: is this a problem? O'Suilleabhain P; Diaz-Arrastia R Arch Neurol; 2004 May; 61(5):633-4. PubMed ID: 15148136 [No Abstract] [Full Text] [Related]
17. Impulse control disorders and dopaminergic drugs. Morgan JC; Iyer SS; Sethi KD Arch Neurol; 2006 Feb; 63(2):298-9; author reply 299. PubMed ID: 16476826 [No Abstract] [Full Text] [Related]
18. Individualization of drug therapy for the parkinsonian patient. JAMA; 1975 Sep; 233(11):1198-201. PubMed ID: 240043 [No Abstract] [Full Text] [Related]
19. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. Müller T; Woitalla D; Kuhn W J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):549. PubMed ID: 12640094 [No Abstract] [Full Text] [Related]
20. Levodopa in the early treatment of Parkinson's disease. Murata M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]